Nano Hospitals
Market Cap
₹365 ₹365 Cr.
P/E
20.47
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.60
Div Yield (%)
Div Yield (%)
-
Individual < 2 lac
Individual < 2 lac
14.24 %
Institutions
Institutions
2.97 %
Market cap
Market cap
365 Cr
No. of Shareholders
No. of Shareholders
1,399
OPM (%)
OPM (%)
19.67 %
PE
PE
20.47
Prom Holding
Prom Holding
61.17 %
ROCE (%)
ROCE (%)
14.97
ROE (%)
ROE (%)
13.06
Sales
Sales
183 Cr
  • Asarfi Hospital Ltd.
  • Rays Of Belief
  • Hannah Joseph Hospit
Last updated on 25 Aug 2026
  • Asarfi Hospital runs 350-bed network, flagship super-specialty plus dedicated cancer institute; care services dominate, shifting beyond cardiac core toward oncology.
  • Earnings ride inpatient volumes and surgeries, led by cancer, cardiology and neurosurgery; occupancy and per-bed realisation swings shape quarters.
  • Per management, defensible Jharkhand moat on cancer/super-specialty infrastructure, referral-led regional reach and patient-first, no-shortcuts care.
  • Expanding via brownfield, acquisition and operations-management models; large PPP medical-college bid and small hospital buy underway.
  • Growth remains collection-constrained; receivables climb faster than revenue, operating cash trails profit and borrowings stay material.
  • Unvalidated reset after Q1 19.9% margin; FY27 revenue guided ₹260Cr, raised from ₹200Cr, EBITDA 23–25%, raised from 17–19%.
  • Top-three concentration stays elevated and surgical-oncology softness exposes earnings to case-mix shifts.
  • Additional 65 super-specialty beds was Mar 2026; no update since
    adds 65 beds; balance beds and occupancy dilution pending.
  • Bone-marrow transplant approval and launch ~Nov–Dec 2026
    new transplant vertical with FY29 contribution expected; approval and capex still needed.
  • Proposed 70–80-bed hospital acquisition FY27 target; no binding date
    adds 70–80-bed hospital; consideration, funding and acquired earnings unresolved.
  • PPP medical college No timeline; bid/financial close needed
    ₹352Cr project with ~₹211Cr grant; equity/debt burden and obligations define funding risk.
  • Cancer capacity toward 150 beds No timeline
    more cancer supply; capex, occupancy and cash conversion shape ramp.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
123
52W Range
High
257
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Distribution Channel

Therapeutic Area Wise Break-Up - API'S

Operational Metrics

    Select a Metric
    • Average Daily Revenue Per Occupied Bed (Rs)
    • Operational Beds (.)
    • Occupancy Rate (%)
    • Number of Outpatient Visits - Quarterly (.)

    Peer Comparison

    FAQs on Asarfi Hospital Ltd. Business

    Asarfi Hospital Limited is an NABL accredited integrated healthcare service provider in Dhanbad, Jharkhand, offering multi-speciality care, prevention, treatment, and rehabilitation services for over 15 years. It is empanelled with Government Agencies, Corporates, Insurance, and TPA providers.

    Asarfi Hospital Ltd. major competitors are Rays Of Belief, Hannah Joseph Hospit, Lotus Eye Hospital, Aashka Hospitals, Vaidya Sane Ayur Lab, Star Imaging & Path, Choksi Laboratories.
    Market Cap of Asarfi Hospital Ltd. is ₹378 Crs.
    While the median market cap of its peers are ₹195 Crs.

    Asarfi Hospital Ltd. seems to be less financially stable compared to its competitors.
    Altman Z score of Asarfi Hospital Ltd. is 4.21 and is ranked 7 out of its 8 competitors.

    Company Filing

    2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Feb May Aug
    Investor Presentation Feb May Aug May Aug Nov Sep Dec
    Conference Call May Mar Nov Sep
    Conference Call SummaryCon Call Summary

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material